Statistics for Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

Total visits

views
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study 0

Total visits per month

views
October 2024 0
November 2024 0
December 2024 0
January 2025 0
February 2025 0
March 2025 0
April 2025 0

File Visits

views
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma_ Caglevic C.pdf 68